News Gilead pushes on with NASH partnership with Novo Nordisk Gilead is one of many pharmas chasing mega-bucks promised by the fatty liver disease known as NASH – but after
News Poxel taking two shots at NASH as pharma waits on FDA's OCA ... Intercept’s obeticholic acid (OCA) is under review in the potentially lucrative fatty liver disease non-alcoholic steatohepatitis (NA
News Novo Nordisk buys rights to NASH drug from Japan's UBE Novo Nordisk has acquired rights to a preclinical drug that could be used to treat non-alcoholic steatohepatitis (NASH), the fatty liver disease that could generate billions of dollars for
News Novartis takes option on NASH drug from Conatus Swiss pharma takes option on FXR agonist emricasan.
News Genfit encounters trial recruitment problem in hunt for NASH... Genfit was among a group of NASH companies publishing updates at the International Liver Congress.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
